●EVER001是一款创新性的共价可逆BTK抑制剂,潜在用于治疗包括原发性膜性肾病等肾脏疾病在内的多种自身免疫性肾脏疾病,有望为全球逾1000万患有原发性膜性肾病、IgA肾病、微小病变性肾病、局灶节段性肾小球硬化和狼疮性肾炎等疾病的患者提供更多治疗选择。●目前全球尚未有药物获得批准用于原发性膜性肾病的治疗。中国目前有约200万原发性膜性肾病患者,而在欧美和日本约有近22万患者。●截至2024年12...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.